Health regulators tightened the checks on treatments, trials and food

Potency, defined before release

The Food and Drug Administration issued final guidance for industry on developing potency assurance strategies for cellular and gene therapy products. The document supersedes the 2011 guidance on potency tests for such products, and it is grounded in quality risk management. The goal of a potency assurance strategy, as the agency defines it, is to ensure that every lot of a product released will have the specific ability or capacity to achieve the intended therapeutic effect. m:…2987

The strategy the guidance describes is not a single test. It includes manufacturing process design and process control, material control, in-process testing and potency lot release assays. The point of listing those elements together is that potency is treated as something built across manufacturing, not something checked once at the end. A product that passes a final assay but was made inconsistently would not meet the standard the guidance describes, and a product made consistently but never tested would not either. m:…2987

The agency is also keeping the conversation open. Its Center for Biologics Evaluation and Research, Office of Therapeutic Products, is hosting a virtual public webinar on December 10, and comments on the guidance can be submitted online or by mail to the Dockets Management office under docket number FDA-2023-D-4299. For developers of cell and gene therapies, the practical consequence is a clearer, risk-based framework to design against, and a public record of how the agency expects potency to be demonstrated lot by lot. m:…2987

Monitoring, widened and made risk-based

The National Institutes of Health proposed a parallel shift in how clinical research is monitored. Its draft policy would update the 1998 data and safety monitoring policy so that it covers all NIH-supported clinical research, rather than only clinical trials. Every project would need an NIH-approved, risk-based monitoring plan, intended to protect data integrity and participant safety while allowing flexibility in how monitoring is done. m:…3036

The most consequential change in the draft is what it removes. It would end the blanket requirement for Data and Safety Monitoring Boards for all phase 3 or multi-site trials, replacing a uniform rule with a risk-based judgment about what level of oversight a given study needs. That is a trade-off worth stating plainly: a risk-based system can focus intensive oversight where the risk is highest, but it also places more weight on the initial risk assessment. If that assessment misses something, the lighter-touch monitoring that follows will be the first place critics look. m:…3036

The proposal is still a proposal, and its timing gives the research community room to respond. Public comments are accepted until January 6, 2027, and the updated policy would take effect for applications submitted on or after six months from the date the final policy is published. That timetable means no research team needs to redesign a monitoring plan tomorrow, but teams planning applications for next year should be reading the draft now, since the framework it sets will shape what their plans must contain. m:…3036

Food and recovery, on the same tour

The third piece of the pattern came from the Department of Health and Human Services, where Secretary Kennedy visited Michigan and Iowa to advance the MAHA initiative, with a focus on nutrition, maternal health and substance use recovery. The tour highlighted a commitment from more than 250 hospitals to provide healthier food options for patients and staff, and the department announced a $12 million investment dedicated to expanding treatment and recovery services in Detroit. m:…1948

Hospital food and addiction treatment may look like separate topics, but they share the logic of the FDA and NIH moves: intervene in the conditions that shape outcomes, rather than only treating the outcome after it arrives. Healthier food in hospitals is a statement about what institutions serve the people in their care. Expanded recovery services in Detroit are a statement about where treatment capacity needs to grow. Neither announcement, on its own, proves a change in health outcomes, and the department's account does not claim otherwise. The commitments and the investment are inputs, and their effects will depend on how hospitals and providers follow through. m:…1948

Taken together, the three developments describe a federal health apparatus that is, for the moment, more interested in assurance than in announcement. The FDA is asking manufacturers to show, lot by lot, that a therapy can do what it claims. The NIH is asking researchers to plan, study by study, how safety and data will be watched. Health officials are asking hospitals to change what they serve and pointing money at recovery services. Whether that emphasis survives contact with budgets, litigation and the comment process is the question to watch, but the direction of travel in this batch of announcements is consistent: build the check into the process, rather than bolting it on afterwards. m:…2987 m:…3036 m:…1948